OIS Index Lags Again in August


The OIS Index of ophthalmic stocks declined 0.4% in August, underperforming its benchmark indices for the second straight month. The NASDAQ Biotechnology Index posted a small gain (+0.9%), while medical device stocks (+3.7%) and the broader US market (+7.1%) continued their strong upward trends.

OIS Index performance in August was negatively impacted by a non-ophthalmic pipeline setback for Unity Biotechnology (–66.7%), which announced that a Phase II study in osteoarthritis failed to meet its primary endpoint. As a result, the company will narrow its near-term focus on ophthalmic and neurologic disease programs.

Apellis Pharmaceuticals (+19.1%) had the largest positive impact on OIS Index performance during the month. The largest percentage gainers, but with smaller impact on index performance due to lower weighting within the index, were KalVista Pharmaceuticals (+33.3%) and Harrow Health (+25.7%).

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol Web

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol

Aura Biosciences Takes Key Steps to Advance Lead Candidate

Aura Biosciences Takes Key Steps to Advance Lead Candidate

Biomedical Informatics Helps Focus Director Dr. Michael Chiang’s Vision for NEI 4

Biomedical Informatics Helps Focus Director Dr. Michael Chiang’s Vision for NEI

MicrosoftTeams-image (49)

Big Things Happening for Kala Pharmaceuticals

MicrosoftTeams-image (22)

New Technology and Teamwork Are Key for Combining Forces

Pioneering Ophthalmic Innovator Patricia Bath, MD, Nominated for National Inventors Hall of Fame (1)

Pioneering Ophthalmic Innovator Patricia Bath, MD, Nominated for National Inventors Hall of Fame

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS